Related references
Note: Only part of the references are listed.A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients
Amy Gye et al.
VALUE IN HEALTH (2022)
The use of innovative payment mechanisms for gene therapies in Europe and the USA
Jesper Jorgensen et al.
REGENERATIVE MEDICINE (2021)
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E. Levine et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications
Melanie D. Whittington et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada
Jill Furzer et al.
JAMA ONCOLOGY (2020)
Managed Entry Agreements: Policy Analysis From the European Perspective
Monique Dabbous et al.
VALUE IN HEALTH (2020)
Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
Andy Eunwoo Kim et al.
CLINICAL DRUG INVESTIGATION (2020)
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
Aris Angelis et al.
PHARMACOECONOMICS (2020)
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
Sissel Michelsen et al.
FRONTIERS IN PHARMACOLOGY (2020)
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Doug Coyle et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Jane F. Barlow et al.
VALUE IN HEALTH (2019)
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
Michael F. Drummond et al.
VALUE IN HEALTH (2019)
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
John K. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Reith R. Sarkar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
Melanie D. Whittington et al.
JAMA NETWORK OPEN (2019)
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Bengt Jonsson et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Luis Felipe Casado et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
Joshua D. Brown et al.
VALUE IN HEALTH (2018)
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
John K. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
Melanie D. Whittington et al.
JAMA PEDIATRICS (2018)
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
Robert Hettle et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
FDA Approval of Tisagenlecleucel Promise and Complexities of a $475 000 Cancer Drug
Peter B. Bach et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Performance-Based Risk-Sharing Arrangements: An Updated International Review
Josh J. Carlson et al.
PHARMACOECONOMICS (2017)
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma
Noemi Muszbek et al.
CLINICAL THERAPEUTICS (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Managed entry agreements for pharmaceuticals in Australia
Agnes Vitry et al.
HEALTH POLICY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Performance-Based Risk-Sharing Arrangements-Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
Louis P. Garrison et al.
VALUE IN HEALTH (2013)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Josh J. Carlson et al.
HEALTH POLICY (2010)
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
Catriona Parker et al.
LANCET (2010)
Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada
Amy C. MacArthur et al.
PEDIATRIC BLOOD & CANCER (2007)
Treatment options for patients with acute myeloid leukemia with a matched sibling donor - A decision analysis
L Sung et al.
CANCER (2003)
Share Paper
